Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Voyager Therapeutics excels in 2022, poised for CNS therapeutic breakthroughs

Voyager Therapeutics demonstrated strong performance in 2022, leveraging key partnerships and advancements in their pipeline programs to drive innovation and growth in the CNS therapeutics space.
While facing challenges in operational clarity and regulatory hurdles, the company's scientific strengths and financial stability position it well to capitalize on opportunities for expanding collaborations and advancing novel therapeutic approaches.
With a focus on CNS delivery, tissue targeting, and surrogate markers, Voyager is poised to make significant strides in addressing neurological disorders and enhancing treatment efficacy, offering potential value for investors and patients alike.

Voyager Therapeutics reports strong Q1 earnings and strategic advancements

Voyager Therapeutics showcased robust financial performance and strategic advancements in neurotherapeutics and gene therapy, positioning the company for future growth.
While facing challenges related to animal model predictability and reimbursement considerations, Voyager is actively leveraging strengths in diversified therapeutic approaches and strategic partnerships.
Opportunities lie in exploring synergistic treatments, proactive risk mitigation, and innovative therapeutic strategies to address complex neurological disorders effectively.
Overall, Voyager's focus on innovation, strategic partnerships, and comprehensive drug development approaches underscores its commitment to advancing treatments for neurological diseases.

Voyager Therapeutics excels in Q2, poised for neurogenetic medicine expansion

Voyager Therapeutics demonstrated strong financial health, innovative advancements in CNS programs, and strategic partnerships driving revenue growth. While facing challenges in R&D management and program milestones, the company's opportunities lie in upcoming milestones and expansion in neurogenetic medicine.

Voyager Therapeutics advances CNS gene therapy with strong partnerships and cash balance

Voyager Therapeutics is making strides in CNS gene therapy delivery with strong financial backing
Facing challenges in toxicology studies and patient recruitment while eyeing collaboration opportunities
Opportunities lie in biomarker utilization, partnership models, and advancing key programs towards clinical milestones

Voyager Therapeutics reports robust earnings and advances in neurogenetic therapies

Voyager Therapeutics showcased a strong financial performance, progress in their pipeline programs, and a focus on innovation and differentiation in the gene therapy space.
While facing competition and regulatory challenges, the company's strategic strengths, collaborations, and positive data present opportunities for future growth and impact.
Analysts' inquiries into program progress and regulatory timelines underscore investor interest in Voyager's development trajectory and the potential of their neurogenetic therapies.
With a robust financial position, promising pipeline advancements, and a commitment to unique approaches, Voyager is poised to make significant strides in the treatment of neurological disorders.

Voyager Therapeutics excels in Q1, eyes Alzheimer's breakthroughs

Voyager Therapeutics demonstrated strong financial performance and pipeline advancements in Q1 2024.
The company's focus on neurogenetic medicine and innovative gene therapy programs is a key strength.
Challenges include demonstrating efficacy in ALS therapy and optimizing brain delivery methods.
Opportunities lie in exploring novel treatment approaches and anticipating key data releases.

Voyager Therapeutics excels in Q2 with innovative pipeline advancements

Voyager Therapeutics demonstrated strong performance in Q2 2024, focusing on key milestones, tau-directed programs, and derisking strategies.
While facing challenges in program optimization and competitive positioning, the company's strengths lie in innovative pipeline advancements and financial stability.
Opportunities for multi-organ specificity, disease-specific programs, and treatment refinement position Voyager for continued growth and therapeutic innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Novartis

Shares of Voyager Therapeutics Inc. (VYGR) jumped Tuesday after the biotech firm agreed to a strategic collaboration and capsid licensing agreement with Novartis AG (NVS) to treat neurological illnesses.

Voyager Therapeutics and Novartis Sign Deal for Neurological Disease Treatments

Voyager Therapeutics (NASDAQ: VYGR ) stock is up by more than 25% today after the company agreed to a licensing deal with Novartis (NYSE: NVS ). Novartis will pay $100 million upfront in a “target-exclusive license” for Voyager's RNA-based screening platform and access to a Huntington's Disease treatment that is in pre-clinical trials.

VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today

Novartis expanded its gene therapy collaboration with Voyager on Monday, and VYGR stock rocketed above its 200-day line.

Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign

Voyager Therapeutics Inc (NASDAQ:VYGR) shares rallied more than 30% in Tuesday pre-market trading after the company announced a strategic collaboration and capsid license agreement worth up to $1.2 billion with Novartis Pharma to advance potential gene therapies for Huntington's disease (HD) and spinal muscular atrophy (SMA). The biotechnology company said it will provide Novartis Pharma, a subsidiary of Novartis AG (ADR) (NYSE:NVS), a target-exclusive license to access its TRACER capsids and other intellectual property for the respective diseases.

Voyager Therapeutics shares pop on collaboration with Novartis worth up to $1.2B

Voyager Therapeutics Inc.'s stock VYGR, -4.20% soared 32% early Tuesday, after the Lexington, Mass.-based biotech announced a new license agreement with Novartis Pharma AG, a unit of Novartis AG.

Voyager Therapeutics shares soar 32% on news of deal with Novartis that includes up to $1.2 billion in milestone payments

Voyager Therapeutics said on Tuesday Novartis would pay it $100 million upfront in cash as part of a licensing deal to develop gene therapy candidates.

Novartis signs gene therapy deal with Voyager for $100 mln upfront

- Collaboration with gene therapy leader Novartis aims to discover and develop new approaches for Huntington's disease and spinal muscular atrophy -

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

Arcturus Therapeutics

Catalyst Pharmaceuticals

Harmony Biosciences Holdings

MacroGenics

Pfizer

Sanofi

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital ecosystem, society will continue to invest in clinical breakthrough stocks in the hopes of forwarding treatments to vexing conditions and diseases.

7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program.

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

Voyager Therapeutics is a biotech firm focused on gene therapy treatments for CNS diseases, with preclinical trials for Parkinson's, ALS, and Alzheimer's. The company's TRACER platform allows for the delivery of therapeutic genes to previously inaccessible brain regions, unlocking potential drug delivery mechanisms. Voyager has secured partnerships and licensing agreements with major pharmaceutical companies, including Novartis, Pfizer, and Neurocrine, showcasing the value of its IP.

Voyager Therapeutics' Strategic Partnerships And TRACER Technology - Speculative Buy

Voyager Therapeutics, Inc. (VYGR) Q3 2023 Earnings Call Transcript

- GLP toxicology studies initiated for VY-TAU01 anti-tau antibody for Alzheimer's disease to enable anticipated 1H 2024 IND filing -

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

CAMBRIDGE, Mass., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report third quarter 2023 financial and operating results after market close on Monday, November 6, 2023. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Executive Officer Alfred W. Sandrock, Jr., M.D., Ph.D., will present at the Chardan 7th Annual Genetic Medicines Conference in New York, NY, on October 2, 2023, at 5:30 p.m. ET.

Voyager Therapeutics to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that management will participate in the following investor conferences:

Voyager Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer (CBO). Shafer is a seasoned healthcare executive with more than 15 years of experience in corporate and business development at prominent biopharmaceutical companies, as well as deep knowledge in neurology. She most recently served as Vice President and Head of R&D Business Development, Gastrointestinal & Inflammation, Neuroscience, Drug Discovery Sciences, Externalizations at Takeda Pharmaceutical Company Ltd.

Voyager Therapeutics Announces Appointment of Beth Shafer as Chief Business Officer

Start Time: 08:30 January 1, 0000 9:08 AM ET Voyager Therapeutics, Inc. (NASDAQ:VYGR ) Q2 2023 Earnings Conference Call August 03, 2023, 08:30 AM ET Company Participants Al Sandrock - President and CEO Pete Pfreundschuh - CFO Todd Carter - Chief Scientific Officer Conference Call Participants Joon Lee - Truist Securities Ingrid Ibarra - Wedbush Jack Allen - Baird Philip Nadeau - TD Cowen Matthew Hershenhorn - Oppenheimer Ross Fladeland - Canaccord Genuity Operator Good morning and welcome to Voyager Therapeutics Second Quarter 2023 Conference Call. All participants are now in a listen-only mode.

Voyager Therapeutics, Inc. (VYGR) Q2 2023 Earnings Call Transcript

- Introduced new vectorized anti-Aβ antibody gene therapy research initiative, expanding Alzheimer's disease portfolio -

Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that Chief Scientific Officer Todd Carter, Ph.D., and Chief Financial Officer Peter Pfreundschuh will participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference on Thursday, August 10, 2023, at 10:30 a.m. ET.

Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference

CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR) a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced it will report second quarter 2023 financial and operating results before the market opens on Thursday, August 3, 2023. Subsequently, the Company will host a conference call and webcast at 8:30 a.m. ET to review its financial and operating results.

Voyager Therapeutics Announces Second Quarter 2023 Conference Call and Webcast

BioNTech SE

Celularity

Chimerix

Innoviva

Regeneron Pharmaceuticals

Zymeworks Inc

Best biotech stocks represents a concept that, no matter what, the market cycle fundamentally delivers relevance. Now, let me back up by stating that no individual company offers a guarantee of success to investors.

Why These 7 Stocks Are the Best Ways to Play Biotech Right Now

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc.

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Sangamo Therapeutics

BRISBANE, Calif. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement for a potential treatment of prion disease. Using its proprietary epigenetic regulation platform, Sangamo has developed zinc finger transcriptional regulators (ZF-TRs) which it believes can specifically and potently block expression of the prion prot.

Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease

Voyager Therapeutics (VYGR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Voyager Therapeutics (VYGR) Moves 7.9% Higher: Will This Strength Last?

Enerplus

Vipshop Hlds

Algoma Steel Group

Dynavax Technologies

Momo

As a rule of thumb, you want to buy quality names in the market, which admittedly rules out several ideas for best stocks under $15 for June. It's not that cheap securities don't exist.

News for Voyager Therapeutics Stock (VYGR)